Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7688)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Sep 27, 2018 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sharafi H, Alavian SM. Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem? World J Hepatol 2018; 10(9): 543-548 [PMID: 30310532 DOI: 10.4254/wjh.v10.i9.543] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v10/i9/543.htm |
| Number | Citing Articles |
| 1 |
Nicole Loo, Bryan Hanysak, Jena Mann, Ruben Ramirez, Jae Kim, Robert Mitchell, Timothy Van Frank, Richard Guerrero, Kim Hinojosa, Kimberley Christensen, Lisa D. Pedicone, Naim Alkhouri, Jennifer Wells, Carmen Landaverde, Fabian Rodas, Eric Lawitz, Fred Poordad. Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance. Medicine 2019; 98(26): e16254 doi: 10.1097/MD.0000000000016254
|
| 2 |
Ezequiel Ridruejo, Matías Javier Pereson, Diego M Flichman, Federico Alejandro Di Lello. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. World Journal of Hepatology 2021; 13(9): 1069-1078 doi: 10.4254/wjh.v13.i9.1069
|
| 3 |
Roaa Khalil, Kholoud Al-Mahzoum, Muna Barakat, Malik Sallam. An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences. Pathogens 2024; 13(8): 674 doi: 10.3390/pathogens13080674
|
| 4 |
Ana Paula de Torres Santos, Vanessa Cristina Martins Silva, Maria Cássia Mendes-Corrêa, Marcilio Figueiredo Lemos, Fernanda de Mello Malta, Rúbia Anita Ferraz Santana, Gregório Tadeu Fernando Dastoli, Vanessa Fusco Duarte de Castro, João Renato Rebello Pinho, Regina Célia Moreira. Prevalence and Pattern of Resistance in NS5A/NS5B in Hepatitis C Chronic Patients Genotype 3 Examined at a Public Health Laboratory in the State of São Paulo, Brazil. Infection and Drug Resistance 2021; : 723 doi: 10.2147/IDR.S247071
|
| 5 |
Nikolay D. Yushchuk, Sergey I. Malov, Igor V Malov, Viktoriya V. Dvornichenko, Rodion I. Rasulov, Patrice N. Marche, Thomas Decaens, Zuzana Macek-Jilkova, Liliya A. Stepanenko, Oleg B. Ogarkov, Larisa S. Orlova. A study of serum miRNA-122 in hepatitis C and associated hepatocellular carcinoma. Annals of the Russian academy of medical sciences 2020; 74(6): 388 doi: 10.15690/vramn1255
|
| 6 |
Ana Paula de Torres Santos, Vanessa Cristina Martins Silva, Maria Cássia Mendes-Corrêa, Marcilio Figueiredo Lemos, Fernanda de Mello Malta, Rúbia Anita Ferraz Santana, Gregório Tadeu Fernando Dastoli, Vanessa Fusco Duarte de Castro, João Renato Rebello Pinho, Regina Célia Moreira. Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis. Revista do Instituto de Medicina Tropical de São Paulo 2022; 64 doi: 10.1590/s1678-9946202264061
|
| 7 |
João Paulo Vilela Rodrigues, Guilherme Rodrigues Fernandes Campos, Cintia Bittar, Ana de Lourdes Candolo Martinelli, Marília Silveira de Almeida Campos, Leonardo Régis Leira Pereira, Paula Rahal, Fernanda Fernandes Souza. Selection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressure. The Brazilian Journal of Infectious Diseases 2022; 26(6): 102717 doi: 10.1016/j.bjid.2022.102717
|
| 8 |
Ebada Mohamed Said, Badawy A. Abdulaziz, Mohamed El Kassas, Ibrahim Hussein El Attar, Mohammed Emadeldeen, Sherief M. Abd-Elsalam. RETRACTED ARTICLE: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience. Archives of Virology 2020; 165(7): 1633 doi: 10.1007/s00705-020-04639-x
|
| 9 |
Pooneh Rahimi, Heidar Sharafi, Golnaz Bahramali, FaridehSadat SajadianFard, Nafiseh Sadat Asadi, Seyed Moayed Alavian, Vahid Iranpur Mobarakeh, Seyedeh Zahra Moravej. Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection. Frontiers in Microbiology 2021; 11 doi: 10.3389/fmicb.2020.617375
|
| 10 |
Imran Shahid, Qaiser Jabeen. Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives. 2023; : 231 doi: 10.2174/9789815123432123010012
|
| 11 |
Zahra Hasanshahi, Ava Hashempour, Farzane Ghasabi, Javad Moayedi, Zahra Musavi, Behzad Dehghani, Heidar Sharafi, Hassan Joulaei. First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients. BMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01988-y
|
| 12 |
Laura Cristina Gómez-Moreno, Samuel David García-Vega, Anlly Paola Pineda-García, María Adelaida Lopera-Baena, Andrés Fernando Rodríguez-Gutiérrez. Antivirales de acción directa contra la hepatitis C: revisión narrativa. Hepatología 2024; 5(2): 123 doi: 10.59093/27112330.109
|